Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study

ダウンロード数 : ? 件

この文献の参照には次のURLをご利用ください : https://ir.lib.shimane-u.ac.jp/52874

言語	英語
著者	杉本利嗣 M. Shiraki Research Institute and Practice for Involutional Diseases, 1610-1 Misatomeisei, Azumino, Nagano, 399-8101, Japan Fukunaga M. Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan Kishimoto H. Nojima Hospital, 2714-1 Sesakimachi, Kurayoshi, Tottori, 682-0863, Japan Hagino H. School of Health Science, Tottori University, 86 Nishicho, Yonago, Tottori, 683-8503, Japan Sone T. Department of Nuclear Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan Nakano T. Tamana Central Hospital, 1950 Naka, Tamana, Kumamoto, 865-0064, Japan Ito M. Center for Diversity and Inclusion, Nagasaki University, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8520, Japan Yoshikawa H. Department of Orthopaedic Surgery, Graduated School of Medicine, Osaka University, 1-1 Yamadaoka, Suita, Osaka, 565-0871, Japan Minamida T. Asahi Kasei Pharma Corporation, 1-1-2 Yurakucho, Chiyoda-ku, Tokyo, 100-0006, Japan Tsuruya Y. Asahi Kasei Pharma Corporation, 1-1-2 Yurakucho, Chiyoda-ku, Tokyo, 100-0006, Japan Nakamura T. Toto Sangenjaya Rehabilitation Hospital, 1-24-3 Sangenjaya, Setagaya-ku, Tokyo, 154-0024, Japan
主題	Teriparatide; Osteoporosis; Bone mineral density; Safety; Twice-weekly; Randomized controlled trial
掲載誌名	OSTEOPOROSIS INTERNATIONAL
巻	30
号	11
開始ページ	2321
終了ページ	2331
ISSN	0937-941X
ISSN（Online）	1433-2965
発行日	2019-11
DOI	10.1007/s00198-019-05111-6
PubMed ID	31392401
出版者	SPRINGER LONDON LTD
資料タイプ	学術雑誌論文
部局	医学部
備考	The study was sponsored and funded by the Asahi Kasei Pharma Corporation, Tokyo, Japan. The sponsor had responsibility for quality control. The corresponding author had full access to all of the data in the study and had responsibility for the decision to submit for publication.; The study was jointly designed by the authors and the sponsor, Asahi Kasei Pharma Corporation. The authors discussed the interpretation of the data and the conclusions of the manuscript with the sponsor. Data analyses for publication were the responsibilities of the sponsor. ToS has received research grants from Astellas Pharma, Eisai, Daiichi-Sankyo, Chugai Pharmaceutical, and Eli Lilly Japan, as well as consulting and/or lecture fees from Asahi Kasei Pharma and Daiichi-Sankyo. MS has received consulting fees from Asahi Kasei Pharma, Chugai Pharmaceutical and Teijin Pharma. HK has received consulting fees from Asahi Kasei Pharma, Chugai Pharmaceutical, Daiichi-Sankyo and EA Pharma. HH has received consulting fees for this study from Asahi Kasei Pharma and lecture fees or grants outside the submitted work from Asahi Kasei Pharma, Astellas Pharma, Chugai Pharmaceutical, Eisai, Eli Lilly Japan, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Ono Pharmaceutical, Pfizer, Taisho Toyama Pharmaceutical, Takeda Pharmaceutical, Teijin Pharma and Daiichi-Sankyo. TeS has received research grants from Asahi Kasei Pharma, Astellas Pharma, Kissei Pharmaceutical, Pfizer, Taisho Toyama Pharmaceutical and Takeda Pharmaceutical. TeN has received consulting fees from Asahi Kasei Pharma. MI has received research grants from Asahi Kasei Pharma, Astellas Pharma, Chugai Pharmaceutical and Daiichi-Sankyo. TM is an employee of Asahi Kasei Pharma. YT is an employee of Asahi Kasei Pharma. ToN has received consulting fees from Asahi Kasei Pharma and Chugai Pharmaceutical, and speaker fees from Daiichi-Sankyo and Taisho Toyama Pharmaceutical.